Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase 1 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT000316817-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)Treatment